Target
Prednisone
31 abstracts
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Abstract
Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.Org: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital),
Abstract
Neurofilament light chains: A biomarker for vincristine-related neuropathy.Org: Ohio State University Comprehensive Canvcer Hospital,
Abstract
Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study.Org: Institut Catala d'Oncologia - Hospital Duran i Reynals, Hematology Department, Hospital 12 de Octubre,
Abstract
Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).Org: Chesapeake Urology Research Associates, Duke Cancer Network,
Abstract
EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma.Org: Manchester Cancer Research Centre, Sir Peter MacCallum Cancer Centre Melbourne, University of Modena and Reggio Emilia,
Abstract
Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).Org: Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, Namık Kemal Üniversitesi, Nantes University Hospital, Centre Hospitalier Universitaire (CHU) de Poitiers,
Abstract
Rituximab, chidamide, and zanubrutinib (ZCR) ± CHOP as a regimen for treatment naive (TN) double-expressor DLBCL (DE-DLBCL).Org: Affiliated Dongguan People’s Hospital, Dongguan People’s Hospital,
Abstract
Efficacy and safety of mosunetuzumab-based regimens as first-line therapy in non-Hodgkin lymphomas: A systematic review of clinical trials.Org: New York Medical College at St.Michael's, New York Medical College at St. Michael’s Medical Center,
Abstract
Rezvilutamide (REZ) plus docetaxel (DOC) in patients (pts) with chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone (ABI).Org: Clinical Trial Center and National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China, Department of Urology Surgery, Hunan Cancer Hospital, Changsha, China, Uro-Oncology, Chongqing University Cancer Hospital, Chongqing, China, Urological Oncology, Sichuan Cancer Hospital, Chengdu, China, Urinary Surgery, The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University, Chongqing, China,
Abstract
The efficacy and safety of ruxolitinib as an add-on therapy to corticosteroids for patients with severe checkpoint inhibitor pneumonitis.Org: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijng, China, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China,
Abstract
Effect of 1-L-MT on immunotherapy of diffuse large B-cell lymphoma via downregulation of PD-L1.Org: Shandong Provincial Qianfoshan Hospital,
Abstract
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma.Org: National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Nagoya City University Graduate School of Medical Sciences, Imamura General Hospital, Kumamoto University Hospital, Kindai University Faculty of Medicine, Osaka-Sayama, Japan,
Abstract
A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).Org: Juravinski Cancer Inst, BCCA, Sindi Ahluwalia Hawkins Centre for the Southern Interior, Princess Margaret - University Health Network, Juravinski Cancer Centre, McMaster University,
Abstract
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.Org: Levine Cancer Institute, Wilmot Cancer Institute, BC Cancer Centre for Lymphoid Cancer, Willamette Valley Cancer Institute and Research Center, US Oncology Research,
Abstract
Evaluation of outcomes between rituximab-abbs and reference product rituximab in adult patients with newly diagnosed diffuse large B-cell lymphoma in a non-inferiority study.Org: Kaiser Permanente Oakland Medical Center, Kaiser Permanante, Kaiser Permanente Davis, Kaiser Permanante Irvine, Kaiser Permanente Pasadena,
Abstract
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.Org: Lymphoma Service, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Vejle Hospital, Universitair Ziekenhuis Gent, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.Org: IRCCS Ospedale Pediatrico Bambino Gesu, University College London Hospitals NHS Foundation Trust, Hospital Universitari Vall d Hebron, Regina Margherita Childrens Hospital and University of Turin, Turin, Italy, Princess Máxima Centrum,
Abstract
Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial.Org: Dana-Farber Cancer Institute, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, Beth Israel Deaconess Medical Center, Janssen Research & Development,
Abstract
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, Seagen, Inc.,
Abstract
CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).Org: Washington University School of Medicine in St Louis, Saint Lukes Hospital,
Abstract
Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.Org: Huntsman Cancer Institute at the University of Utah, University of Utah, Case Western Reserve University School of Medicine, University of Utah/Huntsman Cancer Institute,
Abstract
Immunomodulatory AVM0703 enhances R-CHOP anti-lymphoma effect with reduced toxicity: Immune-resistant, aggressive A20 lymphoma model.Org: AVM Biotechnology, Inc., AVM Biotechnology,
Abstract
Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).Org: Institut Curie, Saint Cloud, France, Institut Curie, Biostatistics Unit, Centre Henri-Becquerel and University of Rouen, Bergonié Institute, Neurology, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière,
Abstract
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.Org: The Peter MacCallum Cancer Centre, Royal Melbourne Hospital, The University of Melbourne, Department of Internal Medicine III, University Hospital Ulm, Klinik für Innere Medizin I, Hämatologie, Onkologie und Stammzelltransplantation Centrum für Chronische Immundefizienz (CCI),
Abstract
3D open-top light-sheet microscopy and 3D microdissection of neuoadjuvant-treated primary prostate cancer reveals latent subclonal mutations.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Allen Brain Institute, Fred Hutchinson Cancer Center/Division of Hematology and Oncology,
Abstract
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.Org: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, Dana-Farber Cancer Institute, Boston, MA, USA, Moffitt Cancer Center and Research Institute, Tampa, FL, Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain, University of Lille, Centre Hospitalier Universitaire, Lille, France,
Abstract
Association of COVID-19 pandemic with indolent lymphoma care delivery and outcomes in Ontario, Canada: A population-based analysis.Org: Princess Margaret Cancer Centre, University Health Network, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Toronto, Institute for Clinical Evaluative Sciences,
Abstract
Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
The association between antibiotics administration and outcomes in men with chemotherapy-naive metastatic castration-resistant prostate cancer: Secondary analysis of two randomized clinical trials.Org: Fudan University Shanghai Cancer Center, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,
Abstract
Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): A phase II study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,